Documente Academic
Documente Profesional
Documente Cultură
DNA Repair
journal homepage: www.elsevier.com/locate/dnarepair
Brief communication
a r t i c l e
i n f o
Article history:
Received 25 June 2013
Received in revised form 29 August 2013
Accepted 31 August 2013
Available online 23 September 2013
Keywords:
ERCC1-XPF
Melanin
Melanoma
Neuroblastoma
Nitrofuran
PARP inhibitor
a b s t r a c t
Nitrofurans are commonly used for the treatment of trypanosomal diseases including Chagas disease.
More recently, following the fortuitous discovery that nifurtimox was clinically active against neuroblastoma, nitrofuran compounds are being investigated for activity against cancer. Herein, we show that
nitrofuran compounds are similarly potent to human malignant melanoma and neuroblastoma cells.
Furthermore, a recently discovered nitrofuran compound, NFN1, was 50- to 175-fold more potent than
nifurtimox against human melanoma and neuroblastoma cell lines. As nitrofuran compounds are known
to act as pro-drugs, producing DNA-damaging reactive intermediates upon activation, we investigated
the DNA repair pathways involved. We show that, contrary to research in Escherichia coli, the Nucleotide
Excision Repair pathway is not required to repair nitrofuran-induced DNA damage in mammalian cells.
Instead, we show that inhibiting repair of single-strand DNA breaks with the poly(ADP-ribose) polymerase (PARP) inhibitor, Olaparib, enhances nitrofuran toxicity in melanoma and neuroblastoma cells.
We propose that this is due to mammalian cells utilising Type 2 nitroreductases for nitrofuran activation
producing Reactive Oxygen Species which cause DNA damage that is repaired by the Single Strand Break
Repair and/or Base Excision Repair pathways, whereas in bacteria and trypanosomes, Type 1 nitroreductases are also utilised resulting in different DNA lesions. In addition we show that, consistent with
Reactive Oxygen Species being formed upon nitrofuran activation and the ability of melanin to absorb
Reactive Oxygen Species, production of melanin in melanoma cells offers some protection from NFN1and hydrogen peroxide-induced toxicity. Our data suggest that combinations of Olaparib and nitrofuran compounds may be advantageous for the treatment of melanoma and neuroblastoma, but that the
protection offered to melanoma cells by their melanin pigment must be taken into account.
2013 Elsevier B.V. All rights reserved.
1. Introduction
Nifurtimox is a nitrofuran compound widely used for the treatment of parasitic infections including Chagas disease, caused by
the Trypanosoma cruzi parasite. Chagas disease is an endemic parasitic disease in areas of Latin America where 7.7 million people are
infected with T. cruzi, with a further 109 million people living at
risk [1]. In 2006, it was discovered fortuitously that nifurtimox was
also clinically active against neuroblastoma [2], suggesting a possible important new role for this compound. It has since undergone
Phase 1 clinical trials for relapsed, or refractory neuroblastoma and
was well-tolerated by paediatric patients, giving tumour responses
as a single or combined agent [3]. Nifurtimox is currently in Phase 2
1001
Fig. 1. Toxicity of nitrofuran compounds on immortalised ERCC1-procient and isogenic ERCC1-decient mouse melanocytes. Toxicity of (A) cisplatin, (B) hydrogen peroxide,
(C) NFN1 and (D) nifurtimox on non-pigmented ERCC1-procient and ERCC1-decient mouse melanocyte cell lines [24]. Growth assays were performed as detailed in Section
2. Cell growth after 6 days was quantied using a Sulphorhodamine B assay [26] and expressed as percentage of the untreated control. Data from two independent experiments
were analysed using SigmaPlot 12.0 (Systat Software Inc.) and IC50 values are shown in Table 1A.
an unstable nitro-radical which, in the presence of oxygen, undergoes futile cycling to generate superoxide (O2 ) and regenerate the
parent nitrofuran [12,13]. In eukaryotes Type 1 nitroreductases are
rarely found, so the predominant mechanism of nitrofuran activation is through Type 2 nitroreductases [11]. It has also recently been
discovered that the aldehyde dehydrogenase (ALDH) 2 enzyme is
capable of bioactivating nitrofurans in zebrash and that nitrofurans are a substrate for human ALDH2 [8].
Nitrofurans cause increased reactive oxygen species (ROS) in
both trypanosomes and eukaryotic cells [12,15,16]. Similarly, the
more potent NFN1 also results in ROS formation in melanoma cells
[8]. In Escherichia coli, where both Type 1 and Type 2 bioactivation
can occur, it is proposed that the Nucleotide Excision Repair (NER)
pathway is required for repair of nitrofuran-induced DNA damage
[17], however this is controversial [18].
Melanocytes produce melanin to protect the skin from UV
radiation. Two main forms of melanin exist: red/yellow pheomelanin is usually converted to the brown/black eumelanin, but in
red-haired individuals with a mutation in the MC1R receptor, conversion does not occur and such individuals have a 3- to 8-fold
increased risk of developing melanoma [19]. Melanin protection
occurs through two distinct mechanisms, rstly by directly absorbing UV to act as a lter, and secondly by scavenging ROS formed
in cells upon UV radiation [20,21]. While eumelanin absorbs ROS,
pheomelanin may actually act as a photosensitizer by producing ROS in response to UV irradiation [22]. As ROS are produced
during nitrofuran activation, we hypothesised that eumelanin
1002
Table 1
(A) IC50 values and fold difference in sensitivity between ERCC1-procient and ERCC1-decient mouse melanocytes (data shown in Fig. 1). (B) IC50 values for NFN1 and
nifurtimox on the human A375 melanoma and SH-5Y5Y neuroblastoma cell lines. NFN1 and nifurtimox IC50 values are shown in the presence and absence of 3 M Olaparib.
Fold difference in toxicity between the IC50 values obtained in the presence and absence of Olaparib are shown (data shown in Fig. 2). (C) IC50 values and fold differences
in sensitivity for NFN1 and hydrogen peroxide on mouse melanoma cells grown under different conditions to produce different levels of pigmentation. Fold differences in
compound IC50 are expressed relative to the IC50 for the heavily pigmented 15% CO2 culture (data shown in Fig. 3). All IC50 values, with 95% Condence Intervals shown
in parentheses, were calculated based upon two independent experiments using SigmaPlot 12.0 (Systat Software Inc.). Statistical signicance between IC50 values was
calculated using a t-test based upon the reported IC50 and SEM by SigmaPlot 12.0.
(A) ERCC1-procient and ERCC-decient mouse melanocytes
Cisplatin
Hydrogen peroxide
NFN1
Nifurtimox
IC50 (ERCC1+)
IC50 (ERCC1)
Fold
P-value
83.21 nM [73.9393.67]
0.44 mM [0.410.47]
0.08 M [0.070.09]
12.59 M [11.6113.65]
6.27 nM [5.656.96]
0.46 mM [0.440.49]
0.05 M [0.040.07]
18.90 M [17.5120.4]
13.3
1.0
1.6
0.7
<0.001
0.990
0.987
<0.001
A375
NFN1
Nifurtimox
SH-5Y5Y
NFN1
Nifurtimox
IC50
Fold
P-value
0.59 M [0.152.36]
29.38 M [26.4432.65]
0.10 M [0.050.19]
18.83 M [16.0922.04]
5.9
1.6
0.029
<0.001
0.33 M [0.240.47]
58.04 M [36.1593.20]
0.18 M [0.130.26]
19.12 M [9.2939.35]
1.8
3.0
0.024
0.018
NFN1
15% CO2
5% CO2
5% CO2 + PTU
Hydrogen peroxide
15% CO2
5% CO2
5% CO2 + PTU
IC50
Fold
P-value
1.66 M [0.972.84]
0.54 M [0.390.74]
0.09 M [0.050.15]
3.1
18.4
<0.001
0.002
1.78 mM [1.582.01]
1.00 mM [0.941.06]
0.91 mM [0.791.07]
1.8
2.0
<0.001
<0.001
2.2. Compounds
Cisplatin (DBL ) was obtained from Faulding Pharmaceuticals.
NFN1 (BTB05727) was obtained from Maybridge and Olaparib
(S1060) was obtained from Stratech Scientic Ltd. Hydrogen peroxide (H1009), nifurtimox (N3415) and phenylthiourea (PTU) (P7629)
were obtained from SigmaAldrich.
2.3. Comet assays
Comet assays were performed as detailed by Olive et al. with
minor alterations [27]. Instead of water, agarose solutions were
prepared in PBS and slides were neutralised with 400 mM Tris
pH7.5. Comets were imaged using a 20 objective and analysed
using CometScoreTM Freeware v1.5 (TriTek Corp.).
3. Results and discussion
repair [28]. As expected, based upon the observed IC50s, ERCC1decient cells were 13-fold more sensitive to cisplatin than their
ERCC1-procient counterparts (see Table 1A). As the mechanism of
nitrofuran-induced DNA damage in eukaryotic cells is believed to
occur by superoxide formation, we utilised hydrogen peroxide to
induce ROS in our cells. As expected, in Fig. 1B, the ERCC1-decient
cells were no more sensitive to hydrogen peroxide than ERCC1procient cells as NER is not involved in the repair of most oxidative
lesions, which are dealt with instead by the BER/SSBR pathways.
To assess whether this was also the case for nitrofuran compounds
we show, in Fig. 1C and D, that the ERCC1-decient cell line was
not hypersensitive to NFN1 or nifurtimox when compared to the
ERCC1-procient line. We conclude that, contrary to the situation in
E. coli [17], the NER pathway is not required for repair of nitrofuraninduced DNA damage in mammalian cells. This could be due to
the different reactive intermediates generated by Type 1 and Type
2 nitroreductases [12,13], with Type 1 resulting in bulky lesions
requiring NER for repair, while Type 2 result in reactive oxygen
species that cause lesions that are substrates for BER/SSBR [12,13].
1003
Fig. 2. Enhancement of NFN1 and nifurtimox toxicity by Olaparib on human melanoma and neuroblastoma cell lines. (A) Showing the NFN1 toxicity on non-pigmented A375
human melanoma cells in the presence, and absence of 3 M Olaparib. In each case, growth is expressed relative to the respective 0 M NFN1 controls, so correcting for any
effect of Olaparib alone on cell growth or cell adhesion after plating. (B) Showing the nifurtimox toxicity on A375 human melanoma cells in the presence, and absence of 3 M
Olaparib. In each case, growth is expressed relative to the respective 0 M nifurtimox controls, so correcting for any effect of Olaparib alone. (C) Showing the NFN1 toxicity on
SH-5Y5Y human neuroblastoma cells [25] in the presence, and absence of 3 M Olaparib. (D) Showing the nifurtimox toxicity on SH-5Y5Y human neuroblastoma cells in the
presence, and absence of 3 M Olaparib. Growth assays were performed as detailed in Materials and methods. Cell growth after 5 (A375) or 6 days (SH-5Y5Y) was quantied
using a Sulphorhodamine B assay [26] and expressed as a percentage of the untreated control. Data from two independent experiments were analysed using SigmaPlot 12.0
(Systat Software Inc.) and IC50 values are shown in Table 1B. (E) Histogram of comet assay on A375 human melanoma cells showing the effect of compound treatment on
the Olive Tail Moment. Cells were treated as indicated with 10 M Olaparib, 200 M NFX, 80 M NFN1, or 100 M hydrogen peroxide for 1 h. Following treatment, Average
Olive Tail Moment values (and SEM), based upon greater than 50 individual comets, are shown. Statistical signicance was determined by t-test and signicance compared
to control is identied by white asterisks, and signicance comparisons to single agents are shown by black asterisks. *P < 0.05, **P < 0.01 and ***P < 0.001. (F) Representative
untreated control comet. (G) Representative hydrogen peroxide-treated comet. (H) Representative NFN1-treated comet. (I) Representative NFN1 and Olaparib-treated
comet.
1004
1005
Fig. 3. Effect of pigmentation on the toxicity of NFN1 and nifurtimox. (A) Bright eld and phase contrast images of the mouse melanoma cell line following culturing at
5% CO2 with 200 M PTU (low level of pigment), 5% CO2 (intermediate pigment level), or 15% CO2 (high pigment level). All images taken using a 10 objective lens. (B)
Toxicity of NFN1 on the mouse melanoma cell line following culturing at 5% CO2 with 200 M PTU, 5% CO2 or 15% CO2 . (C) Toxicity of nifurtimox on the mouse melanoma
cell line following culturing at 5% CO2 with 200 M PTU, 5% CO2 or 15% CO2 . Cell growth was quantied using a Sulphorhodamine B assay [26]. Data from two independent
experiments were analysed using SigmaPlot 12.0 (Systat Software Inc.) and IC50 values are shown in Table 1C. There were no noticeable effects of CO2 level on cell growth
and any minor growth differences between cultures at different CO2 levels were corrected for in the plots where growth curves for the various compounds were expressed
relative to control growth at each CO2 level.
the IC50 was reduced to 0.54 M. Upon further reduction of pigment levels by PTU, the NFN1 IC50 was reduced to 0.09 M. This
demonstrates directly that the presence of pigment in melanoma
cells can result in up to an 18-fold decrease in toxicity to NFN1 (see
Table 1C), analogous to the 11- to 23-fold difference we observed
between pigmented and non-pigmented human melanoma and
mouse melanocyte cell lines. These data are entirely consistent with
the known protective ability of eumelanin to absorb ROS [20,21].
This suggests that the therapeutic window for NFN1 in heavily
pigmented melanomas over non-tumour cells will be reduced. As
expected for another ROS-producer, a pigment-dependent IC50
shift was also observed with hydrogen peroxide, although the difference was smaller than that for NFN1 (Fig. 3C and Table 1C).
Further study of the therapeutic window for NFN1 and nifurtimox against melanoma will be required to determine which
drug would be most effective. An additional complication could
be that the new therapies for melanoma, involving BRAF and/or
MEK inhibitors, can lead to upregulation of MITF and differentiation
markers such as melanin levels [43,44]. By analogy with the relationship between levels of pigmentation and nitrofuran sensitivity
that we report here, this could render BRAF and/or MEK inhibitortreated melanomas more refractory to the nitrofuran therapy that
we have proposed.
3.5. Concluding remarks
We have shown that nitrofuran-induced DNA damage is consistent with the formation of reactive oxygen species generated
by Type 2 nitroreductases. While Nucleotide Excision Repair is not
required to protect against toxicity of NFN1 or nifurtimox in eukaryotic cells, toxicity of both compounds is enhanced by Olaparib,
indicating a role for Base Excision Repair and/or Single Strand Break
Repair. We have shown that the nitrofuran compound NFN1 is more
potent than nifurtimox on human neuroblastoma and melanoma
cell lines, and that combinatorial therapy of NFN1 or nifurtimox
with Olaparib may present a novel therapeutic strategy for both
1006
[18] C. Lu, D.R. McCalla, D.W. Bryant, Action of nitrofurans on E. coli: mutation and
induction and repair of daughter-strand gaps in DNA, Mutat. Res. 67 (1979)
133144.
[19] S. Raimondi, F. Sera, S. Gandini, S. Iodice, S. Caini, P. Maisonneuve, et al., MC1R
variants, melanoma and red hair color phenotype: a meta-analysis, Int. J. Cancer
122 (2008) 27532760.
[20] J.B. Nofsinger, Y. Liu, J.D. Simon, Aggregation of eumelanin mitigates photogeneration of reactive oxygen species, Free Radic. Biol. Med. 32 (2002)
720730.
[21] M. Tada, M. Kohno, Y. Niwano, Scavenging or quenching effect of melanin
on superoxide anion and singlet oxygen, J. Clin. Biochem. Nutr. 46 (2010)
224228.
[22] E. Wenczl, G.P. Van der Schans, L. Roza, R.M. Kolb, A.J. Timmerman, N.P. Smit,
et al., (Pheo)melanin photosensitizes UVA-induced DNA damage in cultured
human melanocytes, J. Invest. Dermatol. 111 (1998) 678682.
[23] K.A. Menear, C. Adcock, R. Boulter, X. Cockcroft, L. Copsey, A. Cranston,
et al., 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-uorobenzyl]2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose)
polymerase-1, J. Med. Chem. 51 (2008) 65816591.
[24] L. Song, A.-M. Ritchie, E.M. McNeil, W. Li, D.W. Melton, Identication of DNA
repair gene Ercc1 as a novel target in melanoma, Pigment Cell Melanoma Res.
24 (2011) 966971.
[25] J.L. Biedler, S. Rofer-Tarlov, M. Schachner, L.S. Freedman, Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones, Cancer Res. 38
(1978) 37513757.
[26] P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, et al., New
colorimetric cytotoxicity assay for anticancer-drug screening, J. Natl. Cancer
Inst. 82 (1990) 11071112.
[27] P.L. Olive, J.P. Banth, The comet assay: a method to measure DNA damage in
individual cells, Nat. Protocols 1 (2006) 2329.
[28] E.M. McNeil, D.W. Melton, DNA repair endonuclease ERCC1XPF as a novel
therapeutic target to overcome chemoresistance in cancer therapy, Nucl. Acids
Res. 40 (2012) 999010004.
[29] P.L. Olive, D.R. McCalla, Damage to mammalian cell DNA by nitrofurans, Cancer
Res. 35 (1975) 781784.
[30] J.I.G. Borroto, G.P. Machado, A. Creus, R. Marcos, Comparative genotoxic evaluation of 2-furylethylenes and 5-nitrofurans by using the comet assay in TK6
cells, Mutagenesis 20 (2005) 193197.
[31] F. Dantzer, V. Schreiber, C. Niedergang, C. Trucco, E. Flatter, G. De La Rubia, et al.,
Involvement of poly(ADP-ribose) polymerase in base excision repair, Biochimie
81 (1999) 6975.
[32] A. Masaoka, J.K. Horton, W.A. Beard, S.H. Wilson, DNA polymerase and PARP
activities in base excision repair in living cells, DNA Repair 8 (2009) 12901299.
[33] C.E. Strm, F. Johansson, M. Uhln, C.A.-K. Szigyarto, K. Erixon, T. Helleday,
Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair
but PARP inhibition traps a single-strand intermediate, Nucleic Acids Res. 39
(2011) 31663175.
[34] S.C. Vilchez Larrea, T. Haikarainen, M. Narwal, M. Schlesinger, H. Venkannagari,
M.M. Flawi, et al., Inhibition of poly(ADP-ribose) polymerase interferes with
Trypanosoma cruzi infection and proliferation of the parasite, PLoS ONE 7 (2012)
e46063.
[35] J.I. Garaycoechea, G.P. Crossan, F. Langevin, M. Daly, M.J. Arends, K.J. Patel, Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem
cell function, Nature 489 (2012) 571575.
[36] M. de Mecca, L.C. Bartel, J.A. Castro, Effect of chronic alcohol drinking on rat
liver microsomal nitroreductive metabolism of nifurtimox and benznidazole,
Hum. Exp. Toxicol. (2013), http://dx.doi.org/10.1177/0960327113485254.
[37] D.C. Bennett, P.J. Cooper, I.R. Hart, A line of non-tumorigenic mouse
melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth, Int. J. Cancer 39 (1987) 414418.
[38] R.K. Singh, T.S. Lange, K.K. Kim, L. Brard, A coumarin derivative (RKS262) inhibits
cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells, Invest. New Drugs 29 (2011) 6372.
[39] B.S. Hall, X. Wu, L. Hu, S.R. Wilkinson, Exploiting the drug-activating properties of a novel trypanosomal nitroreductase, Antimicrob. Agents Chemother.
54 (2010) 11931199.
[40] J. Ackermann, M. Frutschi, K. Kaloulis, T. McKee, A. Trumpp, F. Beermann, Metastasizing melanoma formation caused by expression of activated N-RasQ61K on
an INK4a-decient background, Cancer Res. 65 (2005) 40054011.
[41] A.M. Hall, S.J. Orlow, Degradation of tyrosinase induced by phenylthiourea
occurs following Golgi maturation, Pigment Cell Res. 18 (2005) 122129.
[42] E. Le Pape, K. Wakamatsu, S. Ito, R. Wolber, V.J. Hearing, Regulation of eumelanin/pheomelanin synthesis and visible pigmentation in melanocytes by
ligands of the melanocortin 1 receptor, Pigment Cell Melanoma Res. 21 (2008)
477486.
[43] W.D. Tap, K.-W. Gong, J. Dering, Y. Tseng, C. Ginther, G. Pauletti, et al., Pharmacodynamic characterization of the efcacy signals due to selective BRAF inhibition
with PLX4032 in malignant melanoma, Neoplasia 12 (2010) 637649.
[44] M.P. Smith, J. Ferguson, I. Arozarena, R. Hayward, R. Marais, A. Chapman, et al.,
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma, J.
Natl. Cancer Inst. 105 (2013) 3346.